Pneumococcal 15-valent conjugate vaccine - Biologic Drug Details

Summary for pneumococcal 15-valent conjugate vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for pneumococcal 15-valent conjugate vaccine

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Pneumococcal Vaccine
Chemical Structure	Pneumococcal Vaccines Vaccines, Conjugate Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pneumococcal 15-valent conjugate vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pneumococcal 15-valent conjugate vaccine Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pneumococcal 15-valent conjugate vaccine Derived from Patent Text Search

No patents found based on company disclosures

Pneumococcal 15-valent conjugate vaccine Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Pneumococcal 15-Valent Conjugate Vaccine

Introduction

The pneumococcal 15-valent conjugate vaccine (PCV15) is a significant player in the global pneumococcal vaccine market, driven by its enhanced serotype coverage and the growing need to combat pneumococcal diseases. Here, we delve into the market dynamics and financial trajectory of this vaccine.

Market Size and Growth

The global pneumococcal vaccine market, which includes PCV15, is estimated to be substantial and growing. As of 2023, the market size was approximately USD 8.07 billion and is projected to grow at a CAGR of 6.21% from 2024 to 2030, reaching USD 12.19 billion by 2030[4].

Key Drivers of Market Growth

Several factors are driving the growth of the PCV15 market:

High Prevalence of Pneumococcal Diseases

The high burden of pneumococcal diseases globally, particularly among children and older adults, is a significant driver. For instance, around 2,000 children are affected by pneumonia daily worldwide, highlighting the urgent need for effective vaccines[1].

Government Initiatives and Awareness Programs

Government initiatives and awareness programs play a crucial role in promoting vaccination. For example, India's nationwide rollout of PCV under the Universal Immunisation Programme has boosted vaccine adoption[1].

New Vaccine Developments and Approvals

The development and approval of new vaccines, such as Pfizer's 20-valent pneumococcal conjugate vaccine (Prevnar 20) and Merck's 15-valent pneumococcal conjugate vaccine (V114), are driving market growth. These vaccines offer broader serotype coverage and are expected to replace older vaccines like PCV13[1][3][4].

Economic Evaluations and Cost-Effectiveness

Economic evaluations have shown that PCV15 is a cost-effective strategy compared to PCV13:

Cost Savings and Health Outcomes

Studies have indicated that replacing PCV13 with PCV15 results in significant cost savings and improved health outcomes. For instance, one study found that PCV15 led to total cost savings of over $14 billion and gained 96,056 quality-adjusted life years (QALYs) compared to PCV13[2].

Dominant Strategy

PCV15 has been found to be the dominant strategy even when vaccine prices are slightly higher. For example, a scenario analysis showed that PCV15 remained the dominant strategy with a maximum price per dose 18% higher than PCV13[2].

Regional Market Dynamics

North America

North America holds a significant market share due to its well-established healthcare infrastructure and the presence of key market players like Pfizer and Merck. Government recommendations, such as those from the National Advisory Committee on Immunization (NACI) in Canada, further boost the adoption of PCV15[1][4].

Asia Pacific

The Asia Pacific region is also experiencing growth, driven by increasing awareness about the importance of vaccination and the rising prevalence of pneumococcal infections. Local production facilities and government initiatives are supporting market expansion in this region[4].

Competitive Landscape

The market for pneumococcal vaccines is highly competitive, with several major pharmaceutical companies involved:

Key Players

Pfizer, Merck, and GSK are among the key players. For example, Pfizer's Prevnar 20 and Merck's V114 are recent additions to the market, while GSK's acquisition of Affinivax highlights the competitive and innovative nature of the industry[1][3][4].

Future Outlook

Ongoing Research and Development

Ongoing research and development, such as Sanofi and SK bioscience's 21-valent conjugate vaccine candidate, are expected to further expand the market. These new vaccines aim to offer broader serotype coverage and are likely to increase market share[4].

Government Support and Recommendations

Government support and recommendations will continue to play a crucial role in promoting the use of PCV15. Tools like the PneumoRecs VaxAdvisor app from the CDC help enhance vaccination rates and confidence in vaccines[4].

Public Health Impact

The public health impact of PCV15 is significant:

Reduction in Pneumococcal Disease

Replacing PCV13 with PCV15 is expected to further reduce the incidence of pneumococcal disease. Studies have shown that this replacement could prevent additional pneumococcal disease events and associated deaths, leading to considerable societal cost savings[5].

Key Takeaways

• The pneumococcal 15-valent conjugate vaccine market is driven by high disease prevalence, government initiatives, and new vaccine developments.
• Economic evaluations indicate that PCV15 is a cost-effective strategy compared to PCV13.
• North America and the Asia Pacific region are key markets, with significant growth anticipated.
• The competitive landscape is marked by major pharmaceutical companies continuously innovating and expanding their vaccine portfolios.
• Ongoing research and government support are expected to further boost the market.

FAQs

What is the current market size of the pneumococcal vaccine market?

The global pneumococcal vaccine market size was estimated at USD 8.07 billion in 2023[4].

How is the pneumococcal 15-valent conjugate vaccine expected to grow?

The market is expected to grow at a CAGR of 6.21% from 2024 to 2030, reaching USD 12.19 billion by 2030[4].

What are the key drivers of the PCV15 market?

Key drivers include the high prevalence of pneumococcal diseases, government initiatives, and new vaccine developments and approvals[1][4].

Is PCV15 cost-effective compared to PCV13?

Yes, economic evaluations have shown that PCV15 is a cost-effective strategy, resulting in significant cost savings and improved health outcomes compared to PCV13[2].

Which regions are expected to drive the growth of the PCV15 market?

North America and the Asia Pacific region are expected to drive market growth due to their established healthcare infrastructure and increasing awareness about vaccination[1][4].

Who are the key players in the pneumococcal vaccine market?

Key players include Pfizer, Merck, and GSK, among others[1][3][4].

Sources

1. Mordor Intelligence: Pneumococcal Vaccine Market Size & Share Analysis
2. Canada.ca: Recommendations for public health programs on the use of pneumococcal vaccines
3. Merck: U.S. FDA Accepts for Priority Review the Biologics License Application for V114
4. Grand View Research: Pneumococcal Vaccine Market Size And Share Report, 2030
5. PubMed: Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine